Taylor Steven, Zvolensky Michael J, Cox Brian J, Deacon Brett, Heimberg Richard G, Ledley Deborah Roth, Abramowitz Jonathan S, Holaway Robert M, Sandin Bonifacio, Stewart Sherry H, Coles Meredith, Eng Winnie, Daly Erin S, Arrindell Willem A, Bouvard Martine, Cardenas Samuel Jurado
Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
Psychol Assess. 2007 Jun;19(2):176-88. doi: 10.1037/1040-3590.19.2.176.
Accumulating evidence suggests that anxiety sensitivity (fear of arousal-related sensations) plays an important role in many clinical conditions, particularly anxiety disorders. Research has increasingly focused on how the basic dimensions of anxiety sensitivity are related to various forms of psychopathology. Such work has been hampered because the original measure--the Anxiety Sensitivity Index (ASI)--was not designed to be multidimensional. Subsequently developed multidimensional measures have unstable factor structures or measure only a subset of the most widely replicated factors. Therefore, the authors developed, via factor analysis of responses from U.S. and Canadian nonclinical participants (n=2,361), an 18-item measure, the ASI-3, which assesses the 3 factors best replicated in previous research: Physical, Cognitive, and Social Concerns. Factorial validity of the ASI-3 was supported by confirmatory factor analyses of 6 replication samples, including nonclinical samples from the United States and Canada, France, Mexico, the Netherlands, and Spain (n=4,494) and a clinical sample from the United States and Canada (n=390). The ASI-3 displayed generally good performance on other indices of reliability and validity, along with evidence of improved psychometric properties over the original ASI.
越来越多的证据表明，焦虑敏感性（对与唤醒相关的感觉的恐惧）在许多临床病症中起着重要作用，尤其是焦虑症。研究越来越关注焦虑敏感性的基本维度如何与各种形式的精神病理学相关。这项工作受到了阻碍，因为最初的测量工具——焦虑敏感性指数（ASI）——并非设计为多维的。随后开发的多维测量工具具有不稳定的因子结构，或者只测量了最广泛重复的因子中的一个子集。因此，作者通过对美国和加拿大非临床参与者（n = 2361）的回答进行因子分析，开发了一种18项的测量工具，即ASI - 3，它评估了先前研究中最能重复的三个因子：身体、认知和社交担忧。对6个重复样本进行验证性因子分析，包括来自美国和加拿大、法国、墨西哥、荷兰和西班牙的非临床样本（n = 4494）以及来自美国和加拿大的临床样本（n = 390），支持了ASI - 3的因子效度。ASI - 3在其他可靠性和效度指标上总体表现良好，同时有证据表明其心理测量特性比原始ASI有所改善。
